• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by OraSure Technologies Inc.

    5/20/25 5:26:03 PM ET
    $OSUR
    Medical/Dental Instruments
    Health Care
    Get the next $OSUR alert in real time by email
    S-8 1 osur-formsx82025.htm S-8 Document

    As filed with the Securities and Exchange Commission on May 20, 2025

    Registration No. 333-
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    FORM S-8
    REGISTRATION STATEMENT
    UNDER
    THE SECURITIES ACT OF 1933

    ORASURE TECHNOLOGIES, INC.
    (Exact name of registrant as specified in its charter)
    Delaware 36-4370966
    (State or other jurisdiction of
    incorporation or organization)
    (I.R.S. Employer
    Identification No.)
    220 East First Street
    Bethlehem, Pennsylvania
    18015
    (Address of Principal Executive Offices)(Zip Code)
    ORASURE TECHNOLOGIES, INC. 2000 STOCK AWARD PLAN
    (Full Title of the Plan)

    Carrie Eglinton Manner
    President and Chief Executive Officer
    OraSure Technologies, Inc.
    220 East First Street
    Bethlehem, Pennsylvania 18015
    (Name and address of agent for service)
    (610) 882-1820
    (Telephone number, including area code, of agent for service)
    with a copy to:
    Rachael M. Bushey
    Justin Platt
    Goodwin Procter LLP
    3025 John F. Kennedy Boulevard
    8th Floor
    Philadelphia, PA 19104
    (445) 207-7806
    Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,”



    “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
    Large accelerated filer☐Accelerated filer☒
    Non-accelerated filer☐Smaller reporting company☐
    Emerging growth company☐
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐



    EXPLANATORY NOTE
    This Registration Statement on Form S-8 for OraSure Technologies, Inc. (the “Registrant”) is filed solely to reflect an increase of 6,000,000 shares of the Registrant’s common stock, par value $0.000001 per share (the “Common Stock”), reserved for the OraSure Technologies, Inc. 2000 Stock Award Plan, as amended and restated effective as of March 25, 2024 (the “Plan”). Currently, 13,168,183 shares of Common Stock are registered for issuance under the Plan. Upon the increase of shares as provided in this filing, 19,168,183 shares of Common Stock will be registered for issuance under the Plan. Except as noted below, in accordance with General Instruction E to Form S-8, the contents of Registration Statement No. 333-50340 filed November 20, 2000, the Post Effective Amendments thereto filed on June 27, 2001 and February 14, 2002, Registration Statement No. 333-102235 filed December 27, 2002, Registration Statement No. 333-118385 filed August 20, 2004, Registration Statement No. 333-138814 filed November 17, 2006, Registration Statement No. 333-151077 filed May 21, 2008, Registration Statement No. 333-176315 filed August 15, 2011, Registration Statement No. 333-198237 filed August 19, 2014, Registration Statement No. 333-220148 filed August 24, 2017, Registration Statement No. 333-248424 filed on August 26, 2020, Registration Statement No. 333-270861 filed on March 27, 2023, Registration Statement No. 333-273731 filed on August 4, 2023 and Registration Statement No. 333-281500 filed on August 12, 2024 and are incorporated herein by reference.

    PART I
     
    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS
     
    The information called for in Part I of Form S-8 is not being filed with or included in this Registration Statement (by incorporation by reference or otherwise) in accordance with the rules and regulations of the Securities and Exchange Commission (the “Commission”).

    PART II
    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
    Item 3.Incorporation of Documents by Reference.
    The following documents of the Registrant, filed or to be filed with the Commission are incorporated by reference in this Registration Statement as of their respective dates:
    (a)The Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the Commission on March 7, 2025;

    (b)     The Registrant’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, filed with the Commission on May 7, 2025;

    (c)     The information in the Definitive Proxy Statement on Schedule 14A for the Registrant’s Annual Meeting of Stockholders filed with the Commission on April 4, 2025 to the extent incorporated by reference in Part III of the Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024;

    (d)     The Registrant’s Current Report on Form 8-K filed with the Commission on December 26, 2024 and as amended by the Current Reports on Form 8-K/A filed with the Commission on March 7, 2025 and May 9, 2025;

    (e)    The Registrant’s Current Reports on Form 8-K (other than portions thereof furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits accompanying such reports that are related to such items), filed with the Commission on March 24, 2025, May 9, 2025, and May 14, 2025;

    (f)     The description of the Registrant’s common stock contained in the Registrant’s Registration Statement on Form 8-A12B (File No. 001-16537) as filed with the Commission on June 11, 2001, including any



    amendments or reports filed for the purpose of updating such description, including Exhibit 4.1 to the Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the Commission on March 7, 2025; and

    (g) All documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Securities Exchange Act of 1934, as amended, prior to the filing of a post-effective amendment to this Registration Statement, which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference into this Registration Statement; provided, however, that documents, reports and definitive proxy or information statements, or portions thereof, which are furnished and not filed in accordance with the rules of the Commission shall not be deemed incorporated by reference into this Registration Statement.

    Any statement contained herein or in a document, all or a portion of which is incorporated or deemed to be incorporated by reference herein, shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or amended, to constitute a part of this Registration Statement.

    Item 8.Exhibits.

    The following exhibits are filed herewith or incorporated by reference as part of this Registration Statement:



    Exhibit
    Number
     Description
    4.1
    Certificate of Incorporation of OraSure Technologies, Inc. (incorporated by reference to Exhibit 3.1 to the Registrant’s Registration Statement on Form S-4 (No. 333-39210), filed June 14, 2000).
    4.2
    Certificate of Amendment to Certificate of Incorporation dated May 23, 2000 (incorporated by reference to Exhibit 3.1.1 to the Registrant’s Registration Statement on Form S-4 (No. 333-39210), filed June 14, 2000).
    4.3
    Certificate of Amendment to Certificate of Incorporation dated May 16, 2024 (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K as filed on May 17, 2024).
    4.4
    Second Amended and Restated Bylaws of OraSure Technologies, Inc., as of May 9, 2023 (incorporated by reference to Exhibit 3.1 to the Registrant’s Quarterly Report on Form 10-Q as filed on May 10, 2023).
    4.5
    Specimen certificate representing shares of OraSure Technologies, Inc. $.000001 par value Common Stock is incorporated by reference to Exhibit 4.1 to the Registrant’s Registration Statement on Form S-4 (No. 333-39210).
    5.1* 
    Opinion of Goodwin Procter LLP.
    23.1* 
    Consent of KPMG LLP.
    23.2* 
    Consent of Grant Thornton LLP.
    23.3* 
    Consent of Baker Newman & Noyes LLC.
    23.4* 
    Consent of Goodwin Procter LLP (included in Exhibit 5.1).
    24.1* 
    Power of Attorney (included in signature page to this Registration Statement).
    99.1
    Amended and Restated OraSure Technologies, Inc. 2000 Stock Award Plan (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K as filed on May 14, 2025).
    107*
    Filing Fee Table.
    *Filed Herewith

    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the city of Bethlehem, Commonwealth of Pennsylvania, on this 20th day of May 2025.




    ORASURE TECHNOLOGIES, INC.
    By:/s/ Carrie Eglinton Manner
    Name:Carrie Eglinton Manner
    Title:President and Chief Executive Officer

    POWER OF ATTORNEY
    We, the undersigned officers and directors of OraSure Technologies, Inc., hereby severally constitute and appoint Carrie Eglinton Manner and Kenneth J. McGrath, our true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for such person in such person’s name, place and stead, and in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Commission, granting unto said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite or necessary to be done in and about the premises, as full to all intents and purposes as she or he might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or her or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by the following persons in the capacities held on the dates indicated.




    SignatureTitleDate
    /s/ Carrie Eglinton Manner
    President, Chief Executive Officer and Director
    (principal executive officer)
    May 20, 2025
    Carrie Eglinton Manner
    /s/ Kenneth J. McGrath
    Chief Financial Officer
    (principal financial officer)
    May 20, 2025
    Kenneth J. McGrath
    /s/ Michele AnthonySenior Vice President, Controller & Chief Accounting Officer (principal accounting officer)May 20, 2025
    Michele Anthony
    /s/ Mara G. Aspinall
    DirectorMay 20, 2025
    Mara G. Aspinall
    /s/ Nancy J. Gagliano, M.D.
    DirectorMay 20, 2025
    Nancy J. Gagliano, M.D.
    /s/ John P. KennyDirectorMay 20, 2025
    John P. Kenny
    /s/ Lelio MarmoraDirectorMay 20, 2025
    Lelio Marmora
    /s/ Robert W. McMahonDirectorMay 20, 2025
    Robert W. McMahon
    /s/ David J. Shulkin, M.D.
    DirectorMay 20, 2025
    David J. Shulkin, M.D.



    Get the next $OSUR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $OSUR

    DatePrice TargetRatingAnalyst
    1/3/2023$5.00In-line
    Evercore ISI
    2/24/2022$15.00 → $12.00Buy
    Citigroup
    9/22/2021Outperform → Market Perform
    Raymond James
    8/4/2021$11.00 → $12.50Outperform
    Raymond James
    6/28/2021$12.00 → $11.00Outperform
    Raymond James
    More analyst ratings

    $OSUR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Gagliano Nancy J bought $39,270 worth of shares (12,750 units at $3.08), increasing direct ownership by 16% to 91,524 units (SEC Form 4)

      4 - ORASURE TECHNOLOGIES INC (0001116463) (Issuer)

      3/3/25 9:08:13 AM ET
      $OSUR
      Medical/Dental Instruments
      Health Care
    • President & CEO Eglinton Manner Carrie bought $100,027 worth of shares (28,670 units at $3.49), increasing direct ownership by 2% to 1,288,334 units (SEC Form 4)

      4 - ORASURE TECHNOLOGIES INC (0001116463) (Issuer)

      3/3/25 9:07:25 AM ET
      $OSUR
      Medical/Dental Instruments
      Health Care
    • President & CEO Eglinton Manner Carrie bought $247,378 worth of shares (78,625 units at $3.15), increasing direct ownership by 7% to 1,259,664 units (SEC Form 4)

      4 - ORASURE TECHNOLOGIES INC (0001116463) (Issuer)

      2/27/25 9:14:53 PM ET
      $OSUR
      Medical/Dental Instruments
      Health Care

    $OSUR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Targeted Genomics Announces Commercial Collaboration with OraSure Technologies for Direct to Consumer (DTC) Celiac Genetic Testing

      IRVINE, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Targeted Genomics LLC, developer of GlutenID, the first and only U.S. Food and Drug Administration (FDA) cleared direct-to-consumer (DTC) test for celiac disease genetics, today announced a commercial collaboration with OraSure Technologies, Inc. (NASDAQ:OSUR) manufacturer of ORAcollect®·Dx, the only FDA cleared saliva collection device for general over-the-counter (OTC) use. The collaboration expands consumer access to at-home celiac genetic testing.  Celiac disease, the most common intestinal autoimmune disease worldwide, is triggered by dietary gluten in people who carry the DQ2 and/or DQ8 celiac risk genes. Individuals who test negative

      5/14/25 8:00:00 AM ET
      $OSUR
      Medical/Dental Instruments
      Health Care
    • OraSure Announces First Quarter 2025 Financial Results

      BETHLEHEM, Pa., May 07, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced its financial results for the three months ended March 31, 2025. "Our Q1 results were consistent with our expectations. Our customers continue to demonstrate their preference for our differentiated products in delivering on their important health objectives, even while uncertainty remains elevated related to government funding sources for some segments," said OraSure President and CEO Carrie Eglinton Manner. "We are making good progress in advancing our innovation roadmap, including multiple new prod

      5/7/25 4:05:00 PM ET
      $OSUR
      Medical/Dental Instruments
      Health Care
    • OraSure to Announce First Quarter 2025 Financial Results and Host Earnings Call on May 7th

      BETHLEHEM, Pa., April 23, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR) has scheduled its regular earnings conference call covering first quarter 2025 financial results and certain business developments for 5 p.m. ET on May 7, 2025. A webcast of the conference call will be available on the investor relations page of OraSure's website at https://orasure.gcs-web.com/events-and-presentations. Please click on the webcast link and follow the prompts for registration and access at least 10 minutes prior to the call. The webcast will be archived on OraSure's website shortly after the call has ended and will be available for approximately one year. For participants interested

      4/23/25 4:05:00 PM ET
      $OSUR
      Medical/Dental Instruments
      Health Care

    $OSUR
    SEC Filings

    See more
    • SEC Form EFFECT filed by OraSure Technologies Inc.

      EFFECT - ORASURE TECHNOLOGIES INC (0001116463) (Filer)

      5/30/25 12:15:20 AM ET
      $OSUR
      Medical/Dental Instruments
      Health Care
    • SEC Form S-8 filed by OraSure Technologies Inc.

      S-8 - ORASURE TECHNOLOGIES INC (0001116463) (Filer)

      5/20/25 5:26:03 PM ET
      $OSUR
      Medical/Dental Instruments
      Health Care
    • SEC Form S-3 filed by OraSure Technologies Inc.

      S-3 - ORASURE TECHNOLOGIES INC (0001116463) (Filer)

      5/20/25 5:13:17 PM ET
      $OSUR
      Medical/Dental Instruments
      Health Care

    $OSUR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President & CEO Eglinton Manner Carrie covered exercise/tax liability with 193,249 shares and was granted 335,710 shares, increasing direct ownership by 8% to 1,830,827 units (SEC Form 4)

      4 - ORASURE TECHNOLOGIES INC (0001116463) (Issuer)

      6/5/25 7:16:13 PM ET
      $OSUR
      Medical/Dental Instruments
      Health Care
    • Director Kenny John P. was granted 71,017 shares, increasing direct ownership by 102% to 140,547 units (SEC Form 4)

      4 - ORASURE TECHNOLOGIES INC (0001116463) (Issuer)

      5/15/25 4:46:39 PM ET
      $OSUR
      Medical/Dental Instruments
      Health Care
    • Director Gagliano Nancy J covered exercise/tax liability with 4,387 shares and was granted 71,017 shares, increasing direct ownership by 73% to 158,154 units (SEC Form 4)

      4 - ORASURE TECHNOLOGIES INC (0001116463) (Issuer)

      5/15/25 4:46:26 PM ET
      $OSUR
      Medical/Dental Instruments
      Health Care

    $OSUR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by OraSure Technologies Inc.

      SC 13G/A - ORASURE TECHNOLOGIES INC (0001116463) (Subject)

      11/12/24 4:46:06 PM ET
      $OSUR
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by OraSure Technologies Inc.

      SC 13G/A - ORASURE TECHNOLOGIES INC (0001116463) (Subject)

      11/4/24 1:18:55 PM ET
      $OSUR
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by OraSure Technologies Inc.

      SC 13G - ORASURE TECHNOLOGIES INC (0001116463) (Subject)

      10/4/24 1:30:36 PM ET
      $OSUR
      Medical/Dental Instruments
      Health Care

    $OSUR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Evercore ISI resumed coverage on OraSure with a new price target

      Evercore ISI resumed coverage of OraSure with a rating of In-line and set a new price target of $5.00

      1/3/23 8:07:55 AM ET
      $OSUR
      Medical/Dental Instruments
      Health Care
    • Citigroup reiterated coverage on OraSure Technologies with a new price target

      Citigroup reiterated coverage of OraSure Technologies with a rating of Buy and set a new price target of $12.00 from $15.00 previously

      2/24/22 8:34:18 AM ET
      $OSUR
      Medical/Dental Instruments
      Health Care
    • OraSure Technologies downgraded by Raymond James

      Raymond James downgraded OraSure Technologies from Outperform to Market Perform

      9/22/21 5:02:16 AM ET
      $OSUR
      Medical/Dental Instruments
      Health Care

    $OSUR
    Financials

    Live finance-specific insights

    See more
    • OraSure Announces First Quarter 2025 Financial Results

      BETHLEHEM, Pa., May 07, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced its financial results for the three months ended March 31, 2025. "Our Q1 results were consistent with our expectations. Our customers continue to demonstrate their preference for our differentiated products in delivering on their important health objectives, even while uncertainty remains elevated related to government funding sources for some segments," said OraSure President and CEO Carrie Eglinton Manner. "We are making good progress in advancing our innovation roadmap, including multiple new prod

      5/7/25 4:05:00 PM ET
      $OSUR
      Medical/Dental Instruments
      Health Care
    • OraSure to Announce First Quarter 2025 Financial Results and Host Earnings Call on May 7th

      BETHLEHEM, Pa., April 23, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR) has scheduled its regular earnings conference call covering first quarter 2025 financial results and certain business developments for 5 p.m. ET on May 7, 2025. A webcast of the conference call will be available on the investor relations page of OraSure's website at https://orasure.gcs-web.com/events-and-presentations. Please click on the webcast link and follow the prompts for registration and access at least 10 minutes prior to the call. The webcast will be archived on OraSure's website shortly after the call has ended and will be available for approximately one year. For participants interested

      4/23/25 4:05:00 PM ET
      $OSUR
      Medical/Dental Instruments
      Health Care
    • OraSure Reports Fourth Quarter 2024 Financial Results

      BETHLEHEM, Pa., Feb. 25, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced its financial results for the three months ended December 31, 2024. "Our Q4 revenue was consistent with our expectations, including 10% growth in our core revenue. We continue to see signs of gradual recovery in our key end markets, and we are diversifying our business by expanding our product portfolio and adding new customers, offset by elevated uncertainty for some of our existing customers related to government funding sources," said OraSure President and CEO Carrie Eglinton Manner. "We made tre

      2/25/25 4:05:00 PM ET
      $OSUR
      Medical/Dental Instruments
      Health Care

    $OSUR
    Leadership Updates

    Live Leadership Updates

    See more
    • KKR, CrowdStrike Holdings and GoDaddy Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

      NEW YORK, June 7, 2024 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, June 24, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P SmallCap 600 are more representative of the small-cap market space. The companies being removed from the S

      6/7/24 6:09:00 PM ET
      $ADTN
      $ALTR
      $ATNI
      $BMRN
      Telecommunications Equipment
      Utilities
      Computer Software: Prepackaged Software
      Technology
    • NOWDiagnostics Welcomes Dr. Stephen S. Tang as Chairman of the Board

      Former Head of OraSure Technologies Joins at Key Stage Leading up to Company's Product Launch NOWDiagnostics (NOWDx), a developer of over-the-counter (OTC) and point-of-care (POC) diagnostics tests and first-in-class technology and platforms, today announced the appointment of Dr. Stephen S. Tang, Ph.D., MBA, as the chairman of the company's board of directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240321747977/en/NOWDiagnostics (NOWDx) Welcomes Dr. Stephen S. Tang as Chairman of the Board (Photo: Business Wire) Dr. Tang is a longtime veteran of the medical diagnostic industry. He led OraSure Technologies, Inc. (NASDA

      3/21/24 8:31:00 AM ET
      $OSUR
      Medical/Dental Instruments
      Health Care
    • OraSure Technologies Announces the Retirement of Jack E. Jerrett and Appointment of Agnieszka M. Gallagher as General Counsel, Chief Compliance Officer and Secretary

      BETHLEHEM, Pa., Nov. 09, 2021 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR), a global leader in point-of-care and home diagnostic testing and sample collection technologies, announced today that after almost 21 years of service to the Company, Jack E. Jerrett is retiring as the Company's Senior Vice President, General Counsel, Chief Compliance Officer and Secretary, effective as of December 31, 2021. Agnieszka M. Gallagher, who most recently served as the Chief Ethics and Compliance Officer at Alnylam Pharmaceuticals has been hired by the Company to fill Jack's roles as the new General Counsel, Chief Compliance Officer and Secretary. "Jack has been a stalwart and extremely

      11/9/21 7:05:00 AM ET
      $OSUR
      Medical/Dental Instruments
      Health Care